Journal
MOLECULAR THERAPY
Volume 21, Issue 3, Pages 509-519Publisher
CELL PRESS
DOI: 10.1038/mt.2012.280
Keywords
-
Categories
Funding
- NIH [EY021721, R24EY022012, T32 EY00713]
- Macula Vision Research Foundation
- Foundation Fighting Blindness
- Eldon Family Foundation
- Creed's Cause Foundation
- Vision for Children and Research to Prevent Blindness, Inc.
Ask authors/readers for more resources
Blindness, although not life threatening, is a debilitating disorder for which few, if any treatments exist. Ocular gene therapies have the potential to profoundly improve the quality of life in patients with inherited retinal disease. As such, tremendous focus has been given to develop such therapies. Several factors make the eye an ideal organ for gene-replacement therapy including its accessibility, immune privilege, small size, compartmentalization, and the existence of a contralateral control. This review will provide a comprehensive summary of (i) existing gene therapy clinical trials for several genetic forms of blindness and (ii) preclinical efficacy and safety studies in a variety of animal models of retinal disease which demonstrate strong potential for clinical application. To be as comprehensive as possible, we include additional proof of concept studies using gene replacement, neurotrophic/neuroprotective, optogenetic, antiangiogenic, or antioxidative stress strategies as well as a description of the current challenges and future directions in the ocular gene therapy field to this review as a supplement.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available